A O O O O
number O O O O
of O O O O
agreements O O O O
for O O O O
Numerate O O O O
Company O O O O
inks O O O O
deals O O O O
with O O O O
Takeda, O O O O
Servier O O O O
to O O O O
leverage O O O O
AI-driven O O O O
drug O O O O
discovery O O O O
platform O O O O
SAN O O O O
BRUNO, O O O O
Calif.â€”June O O O O
has O O O O
started O O O O
on O O O O
a O O O O
busy O O O O
note O O O O
for O O O O
[Numerate O O O O
Inc.](http://www.numerate.com/), O O O O
a O O O O
computational O O O O
drug O O O O
design O O O O
company O O O O
that O O O O
uses O O O O
artificial O O O O
intelligence O O O O
(AI) O O O O
at O O O O
cloud O O O O
scale O O O O
in O O O O
small-molecule O O O O
drug O O O O
discovery, O O O O
as O O O O
the O O O O
company O O O O
has O O O O
announced O O O O
partnerships O O O O
with O O O O
two O O O O
industry O O O O
giants O O O O
within O O O O
a O O O O
week. O O O O
The O O O O
most O O O O
recent O O O O
deal O O O O
is O O O O
a O O O O
multi-year O O O O
agreement O O O O
with O O O O
[Takeda O O O O
Pharmaceutical O O O O
Co. O O O O
Ltd.](https://www.takeda.com/)to O O O O
identify O O O O
and O O O O
deliver O O O O
a O O O O
number O O O O
of O O O O
clinical O O O O
candidates. O O O O
Per Reason 3 O O
the Reason 3 O O
terms Reason 3 O O
of Reason 3 O O
the Reason 3 O O
agreement, Reason 3 O O
Numerate Reason 3 O O
will Reason 3 O O
lead Reason 3 O O
drug Reason 3 O O
discovery Reason 3 O O
programs Reason 3 O O
to Reason 3 O O
identify Reason 3 O O
clinical Reason 3 O O
candidates Reason 3 O O
in Reason 3 O O
Takeda's Reason 3 O O
core Reason 3 O O
therapeutic Reason 3 O O
areas, Reason 3 O O
which Reason 3 O O
includes Reason 3 O O
oncology, Reason 3 O O
gastroenterology Reason 3 O O
and Reason 3 O O
central Reason 3 O O
nervous Reason 3 O O
system Reason 3 O O
disorders. Reason 3 O O
While O O O O
no O O O O
financial O O O O
terms O O O O
were O O O O
released, O O O O
Numerate O O O O
did O O O O
note O O O O
in O O O O
a O O O O
press O O O O
release O O O O
that O O O O
the O O O O
deal O O O O
includes O O O O
"a O O O O
combination O O O O
of O O O O
milestone O O O O
payments O O O O
and O O O O
royalties O O O O
that O O O O
reflect O O O O
the O O O O
value O O O O
of O O O O
the O O O O
clinical O O O O
candidates O O O O
being O O O O
delivered." O O O O
"We Reason 4 O O
are Reason 4 O O
excited Reason 4 O O
to Reason 4 O O
partner Reason 4 O O
with Reason 4 O O
Numerate. Reason 4 O O
Numerate Reason 4 O O
has Reason 4 O O
established Reason 4 O O
an Reason 4 O O
impressive Reason 4 O O
track Reason 4 O O
record Reason 4 O O
of Reason 4 O O
leveraging Reason 4 O O
their Reason 4 O O
AI Reason 4 O O
platform Reason 4 O O
to Reason 4 O O
overcome Reason 4 O O
drug Reason 4 O O
design Reason 4 O O
challenges, Reason 4 O O
both Reason 4 O O
for Reason 4 O O
its Reason 4 O O
own Reason 4 O O
pipeline Reason 4 O O
and Reason 4 O O
in Reason 4 O O
pharma/biotech Reason 4 O O
collaborations," Reason 4 O O
David Reason 4 O O
Weitz, Reason 4 O O
head Reason 4 O O
of Reason 4 O O
Takeda Reason 4 O O
California Reason 4 O O
and Reason 4 O O
Global Reason 4 O O
Research Reason 4 O O
Externalization, Reason 4 O O
said Reason 4 O O
in Reason 4 O O
a Reason 4 O O
press Reason 4 O O
release. Reason 4 O O
"By Reason 4 O O
having Reason 4 O O
Numerate Reason 4 O O
select Reason 4 O O
projects Reason 4 O O
that Reason 4 O O
align Reason 4 O O
with Reason 4 O O
Takeda's Reason 4 O O
strategy, Reason 4 O O
we Reason 4 O O
expect Reason 4 O O
the Reason 4 O O
partnership Reason 4 O O
to Reason 4 O O
yield Reason 4 O O
multiple Reason 4 O O
assets Reason 4 O O
that Reason 4 O O
Takeda Reason 4 O O
can Reason 4 O O
develop Reason 4 O O
into Reason 4 O O
truly Reason 4 O O
transformative Reason 4 O O
medicines Reason 4 O O
for Reason 4 O O
patients." Reason 4 O O
Numerate O O O O
explains O O O O
on O O O O
its O O O O
site O O O O
that O O O O
its O O O O
platform O O O O
enables O O O O
faster, O O O O
more O O O O
efficient O O O O
lead O O O O
optimization/candidate O O O O
identification, O O O O
as O O O O
well O O O O
as O O O O
predictive O O O O
ADME O O O O
models, O O O O
adding O O O O
that O O O O
"Our Reason 5 O O
approach Reason 5 O O
can Reason 5 O O
capture Reason 5 O O
the Reason 5 O O
non-linearities Reason 5 O O
inherent Reason 5 O O
in Reason 5 O O
ADME Reason 5 O O
due Reason 5 O O
to Reason 5 O O
the Reason 5 O O
interplay Reason 5 O O
of Reason 5 O O
physical Reason 5 O O
and Reason 5 O O
biological Reason 5 O O
assay Reason 5 O O
structure, Reason 5 O O
biochemical Reason 5 O O
interactions Reason 5 O O
and Reason 5 O O
physicochemical Reason 5 O O
properties. Reason 5 O O
We Reason 5 O O
can Reason 5 O O
model Reason 5 O O
many Reason 5 O O
of Reason 5 O O
the Reason 5 O O
most Reason 5 O O
important Reason 5 O O
ADME Reason 5 O O
properties, Reason 5 O O
including Reason 5 O O
intestinal Reason 5 O O
absorption, Reason 5 O O
active Reason 5 O O
efflux Reason 5 O O
pumping Reason 5 O O
and Reason 5 O O
metabolic Reason 5 O O
stability. Reason 5 O O
Our Reason 5 O O
ADME Reason 5 O O
models Reason 5 O O
outperform Reason 5 O O
the Reason 5 O O
best Reason 5 O O
methods Reason 5 O O
in Reason 5 O O
the Reason 5 O O
literature, Reason 5 O O
increasing Reason 5 O O
accuracy Reason 5 O O
as Reason 5 O O
the Reason 5 O O
drug Reason 5 O O
program Reason 5 O O
moves Reason 5 O O
forward." Reason 5 O O
"This O O O O
is O O O O
an O O O O
ideal O O O O
arrangement O O O O
for O O O O
Numerate O O O O
because O O O O
our O O O O
team O O O O
will O O O O
be O O O O
working O O O O
largely O O O O
independently O O O O
while O O O O
having O O O O
the O O O O
opportunity O O O O
to O O O O
leverage O O O O
Takeda's O O O O
global O O O O
experience, O O O O
therapeutic O O O O
area O O O O
insights O O O O
and O O O O
unique O O O O
R&D O O O O
capabilities," O O O O
commented O O O O
Guido O O O O
Lanza, O O O O
president O O O O
and O O O O
CEO O O O O
of O O O O
Numerate. O O O O
"We O O O O
expect O O O O
to O O O O
produce O O O O
multiple O O O O
clinical O O O O
candidates, O O O O
while O O O O
also O O O O
continuing O O O O
to O O O O
refine, O O O O
validate O O O O
and O O O O
expand O O O O
our O O O O
proprietary O O O O
AI-driven O O O O
platform O O O O
as O O O O
we O O O O
work O O O O
across O O O O
a O O O O
broad O O O O
range O O O O
of O O O O
target O O O O
types O O O O
and O O O O
drug O O O O
design O O O O
challenges." O O O O
Several O O O O
days O O O O
before O O O O
that O O O O
announcement, O O O O
on O O O O
June O O O O
9, O O O O
Numerate O O O O
shared O O O O
news O O O O
of O O O O
a O O O O
collaboration O O O O
with O O O O
[Servier](http://www.servier.com/)for O O O O
the O O O O
design O O O O
of O O O O
small-molecule O O O O
modulators O O O O
of O O O O
the O O O O
ryanodine O O O O
receptor O O O O
2 O O O O
(RyR2), O O O O
which O O O O
has O O O O
been O O O O
highlighted O O O O
as O O O O
playing O O O O
a O O O O
role O O O O
in O O O O
cardiovascular O O O O
diseases O O O O
and O O O O
being O O O O
difficult O O O O
to O O O O
drug. O O O O
Dysfunction O O O O
of O O O O
this O O O O
receptor O O O O
is O O O O
linked O O O O
with O O O O
the O O O O
defects O O O O
in O O O O
calcium O O O O
handling O O O O
that O O O O
typify O O O O
cardiovascular O O O O
diseases. O O O O
As O O O O
noted O O O O
on O O O O
[GeneCards.org](http://www.genecards.org/), O O O O
"Mutations O O O O
in O O O O
this O O O O
gene O O O O
are O O O O
associated O O O O
with O O O O
stress-induced O O O O
polymorphic O O O O
tachycardia O O O O
and O O O O
arrhythmogenic O O O O
right O O O O
ventricular O O O O
Numerate O O O O
has O O O O
identified O O O O
several O O O O
novel O O O O
RyR2 O O O O
modulators. O O O O
The O O O O
collaboration O O O O
between O O O O
Numerate O O O O
and O O O O
Servier O O O O
includes O O O O
modeling O O O O
all O O O O
aspects O O O O
of O O O O
small-molecule O O O O
drug O O O O
discovery, O O O O
leveraging O O O O
available O O O O
chemical O O O O
and O O O O
biological O O O O
data O O O O
and O O O O
applying O O O O
Numerate's O O O O
technology. O O O O
Servier O O O O
has O O O O
licensed O O O O
Numerate's O O O O
RyR2 O O O O
program, O O O O
including O O O O
the O O O O
novel O O O O
compounds O O O O
that O O O O
have O O O O
been O O O O
identified. O O O O
Numerate O O O O
will O O O O
be O O O O
responsible O O O O
for O O O O
supporting O O O O
efforts O O O O
in O O O O
assay O O O O
development, O O O O
lead O O O O
design O O O O
and O O O O
optimization. O O O O
No O O O O
financial O O O O
details O O O O
were O O O O
released. O O O O
"Numerate's Reason 3 O O
platform Reason 3 O O
has Reason 3 O O
literally Reason 3 O O
cracked Reason 3 O O
the Reason 3 O O
code Reason 3 O O
on Reason 3 O O
rapidly Reason 3 O O
identifying Reason 3 O O
diverse, Reason 3 O O
potent, Reason 3 O O
and Reason 3 O O
functionally Reason 3 O O
active Reason 3 O O
modulators Reason 3 O O
of Reason 3 O O
the Reason 3 O O
ryanodine Reason 3 O O
receptor," Reason 3 O O
said Reason 3 O O
Dr. Reason 3 O O
Isabelle Reason 3 O O
Tupinon-Mathieu, Reason 3 O O
vice Reason 3 O O
president Reason 3 O O
of Reason 3 O O
Research Reason 3 O O
and Reason 3 O O
Development Reason 3 O O
and Reason 3 O O
Head Reason 3 O O
of Reason 3 O O
Cardiovascular Reason 3 O O
and Reason 3 O O
Metabolism Reason 3 O O
Therapeutic Reason 3 O O
Innovation Reason 3 O O
Poles Reason 3 O O
at Reason 3 O O
Servier. Reason 3 O O
"Our Reason 3 O O
collaboration Reason 3 O O
will Reason 3 O O
leverage Reason 3 O O
our Reason 3 O O
proprietary Reason 3 O O
data Reason 3 O O
to Reason 3 O O
accelerate Reason 3 O O
the Reason 3 O O
design Reason 3 O O
of Reason 3 O O
new Reason 3 O O
and Reason 3 O O
efficient Reason 3 O O
molecules Reason 3 O O
and Reason 3 O O
advance Reason 3 O O
our Reason 3 O O
cardiovascular Reason 3 O O
program Reason 3 O O
toward Reason 3 O O
